For centuries, nature, and particularly the innate immune system, has encoded powerful mechanisms for disease control and repair. Today, artificial intelligence (AI) is reshaping drug discovery by revealing these signals with unprecedented resolution and by transforming how companies even run experiments, closing the loop between computation and the lab. Panelists will share their experience in learning directly from human-relevant biological data and how AI is enabling the discovery of antibody drugs, small molecules, and new therapeutic modalities that harness the body’s own regulatory systems. As experimentation becomes faster, more adaptive, and increasingly automated, these approaches are uncovering targets that have long eluded traditional R&D - accelerating discovery, reducing risk, and redefining how modern medicines are designed.